Eli Lilly and Company $LLY Shares Sold by Nwam LLC

Nwam LLC lowered its position in shares of Eli Lilly and Company (NYSE:LLY) by 4.0% during the 4th quarter, HoldingsChannel reports. The institutional investor owned 14,675 shares of the company’s stock after selling 618 shares during the quarter. Eli Lilly and Company comprises about 0.9% of Nwam LLC’s investment portfolio, making the stock its 19th largest position. Nwam LLC’s holdings in Eli Lilly and Company were worth $15,617,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently bought and sold shares of the company. D Orazio & Associates Inc. raised its stake in Eli Lilly and Company by 15.0% during the fourth quarter. D Orazio & Associates Inc. now owns 2,059 shares of the company’s stock valued at $2,213,000 after buying an additional 268 shares in the last quarter. Advisor OS LLC boosted its holdings in Eli Lilly and Company by 11.0% in the fourth quarter. Advisor OS LLC now owns 6,741 shares of the company’s stock worth $7,245,000 after purchasing an additional 668 shares during the period. Plato Investment Management Ltd boosted its holdings in Eli Lilly and Company by 3.6% in the fourth quarter. Plato Investment Management Ltd now owns 18,125 shares of the company’s stock worth $19,574,000 after purchasing an additional 633 shares during the period. Midwest Trust Co boosted its holdings in Eli Lilly and Company by 26.8% in the fourth quarter. Midwest Trust Co now owns 63,621 shares of the company’s stock worth $68,372,000 after purchasing an additional 13,464 shares during the period. Finally, Bensler LLC boosted its holdings in Eli Lilly and Company by 5.4% in the fourth quarter. Bensler LLC now owns 19,681 shares of the company’s stock worth $21,151,000 after purchasing an additional 1,014 shares during the period. Institutional investors and hedge funds own 82.53% of the company’s stock.

Eli Lilly and Company Trading Down 0.0%

Shares of NYSE:LLY opened at $948.01 on Monday. The company has a 50 day moving average of $943.90 and a 200-day moving average of $990.90. The firm has a market cap of $892.78 billion, a P/E ratio of 33.68, a P/E/G ratio of 1.03 and a beta of 0.48. Eli Lilly and Company has a twelve month low of $623.78 and a twelve month high of $1,133.95. The company has a current ratio of 1.50, a quick ratio of 1.10 and a debt-to-equity ratio of 1.26.

Eli Lilly and Company (NYSE:LLY) last issued its quarterly earnings results on Thursday, April 30th. The company reported $8.55 earnings per share (EPS) for the quarter, beating the consensus estimate of $6.97 by $1.58. Eli Lilly and Company had a return on equity of 105.77% and a net margin of 34.98%.The company had revenue of $19.80 billion for the quarter, compared to analysts’ expectations of $17.82 billion. During the same period last year, the firm earned $3.34 EPS. The firm’s revenue for the quarter was up 55.5% on a year-over-year basis. Eli Lilly and Company has set its FY 2026 guidance at 35.500-37.000 EPS. As a group, analysts anticipate that Eli Lilly and Company will post 35.8 earnings per share for the current fiscal year.

Eli Lilly and Company Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Wednesday, June 10th. Shareholders of record on Friday, May 15th will be issued a $1.73 dividend. This represents a $6.92 dividend on an annualized basis and a yield of 0.7%. The ex-dividend date of this dividend is Friday, May 15th. Eli Lilly and Company’s dividend payout ratio is presently 24.58%.

Wall Street Analysts Forecast Growth

A number of research analysts recently issued reports on LLY shares. BMO Capital Markets restated an “outperform” rating and set a $1,300.00 price objective on shares of Eli Lilly and Company in a research report on Thursday, February 5th. CICC Research boosted their price objective on Eli Lilly and Company from $1,060.00 to $1,107.00 and gave the company a “neutral” rating in a research report on Wednesday, February 11th. Loop Capital set a $1,200.00 price objective on Eli Lilly and Company in a research report on Tuesday, February 10th. Freedom Capital upgraded Eli Lilly and Company from a “hold” rating to a “strong-buy” rating in a research report on Tuesday, February 10th. Finally, Truist Financial reaffirmed a “buy” rating on shares of Eli Lilly and Company in a report on Monday, February 23rd. Two investment analysts have rated the stock with a Strong Buy rating, twenty-three have assigned a Buy rating, four have issued a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, Eli Lilly and Company currently has a consensus rating of “Moderate Buy” and an average target price of $1,218.33.

Key Eli Lilly and Company News

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Rothschild & Co Redburn raised its price target on Eli Lilly to $900 from $880, signaling continued confidence in the company’s long-term value despite the target still sitting below the recent share price. MarketScreener
• Positive Sentiment: Multiple reports highlighted strong demand for Lilly’s GLP-1 medicines, including Mounjaro, with first-quarter sales described as a major driver of revenue growth and a key reason investors remain optimistic about future earnings. Motley Fool
• Positive Sentiment: Reuters reported that early weight-loss pill data is boosting Lilly and Novo Nordisk by raising hopes the market could expand beyond injections to millions more patients, which could support a larger long-term revenue opportunity. Reuters
• Positive Sentiment: Lilly announced an additional $4.5 billion investment in Indiana manufacturing sites, reinforcing confidence in its ability to meet future demand for weight-loss and other therapies while expanding U.S. production capacity. Benzinga
• Neutral Sentiment: Several commentary pieces continued to frame Lilly as a high-quality growth stock, but these were largely reiterations of the bullish long-term thesis rather than fresh catalysts. Zacks
• Neutral Sentiment: Articles about shareholder support for the board and broader analyst upgrades suggest stable governance and sentiment, but they do not appear to be major standalone trading catalysts. TipRanks
• Negative Sentiment: One article noted that Eli Lilly’s valuation remains rich and that some investors see more upside in competitors, which can limit enthusiasm even when fundamentals are strong. Motley Fool

Eli Lilly and Company Company Profile

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.